Interventions
Where each approach stands and the latest research in our collection. Every overview links to its background sources and recent updates; detailed AI reviews are available where completed.
40 tracked topics · AI-written overviews, not expert-reviewed · Recent updates cover the last 30 days.
- Acarbose
Experimental off label · 1 collected reports
Acarbose has extended lifespan in the National Institute on Aging’s mouse testing program, making it an interesting candidate for ageing research. Repeated animal results help justify investigation, but do not determine whether a diabetes medicine benefits people without diabetes or extends human life. Human clinical outcomes are the important next test of the longevity hypothesis. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.
AI review not yet available
Explore research → - Metformin
Experimental off label · 26 collected reports
Metformin is a diabetes medicine being investigated for effects on ageing-related biology. Laboratory findings and studies in people with metabolic disease make it a plausible research candidate, but they do not establish that otherwise healthy adults live longer by taking it. The key unresolved question is whether it prevents meaningful age-related illness, rather than merely changing laboratory markers. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 27, 2026: “FEAST and HOPE: Redox PSC Pilot Study in PSC”. Its implications have not yet been summarized in a source-checked review. Read update ↗
AI review not yet available
Explore research → - Rapamycin
Experimental off label · 30 collected reports
Rapamycin is a prominent experimental longevity candidate because lifespan extension has been reproduced in the National Institute on Aging’s mouse testing program. That is stronger animal evidence than a single laboratory experiment, but it remains animal evidence. It does not establish an effective, safe life-extension treatment for people or justify translating a mouse regimen into personal use. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.
AI review not yet available
Explore research →
| Intervention | Current state & recent changes | Research & review |
|---|---|---|
| Acarbose Experimental off label | Acarbose has extended lifespan in the National Institute on Aging’s mouse testing program, making it an interesting candidate for ageing research. Repeated animal results help justify investigation, but do not determine whether a diabetes medicine benefits people without diabetes or extends human life. Human clinical outcomes are the important next test of the longevity hypothesis. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged. Explore research → | 1 collected reports AI review not yet available |
| Metformin Experimental off label | Metformin is a diabetes medicine being investigated for effects on ageing-related biology. Laboratory findings and studies in people with metabolic disease make it a plausible research candidate, but they do not establish that otherwise healthy adults live longer by taking it. The key unresolved question is whether it prevents meaningful age-related illness, rather than merely changing laboratory markers. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 27, 2026: “FEAST and HOPE: Redox PSC Pilot Study in PSC”. Its implications have not yet been summarized in a source-checked review. Read update ↗ Explore research → | 26 collected reports AI review not yet available |
| Rapamycin Experimental off label | Rapamycin is a prominent experimental longevity candidate because lifespan extension has been reproduced in the National Institute on Aging’s mouse testing program. That is stronger animal evidence than a single laboratory experiment, but it remains animal evidence. It does not establish an effective, safe life-extension treatment for people or justify translating a mouse regimen into personal use. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged. Explore research → | 30 collected reports AI review not yet available |